CD63 and neoplasm: Most encouragingly, targeting the CD9+ EVs and aptamer recognition of CD63/EpCAM/MUC1 (epithelial markers), carcinomas were detected with 100% sensitivity and specificity, indicating that specific targeting of tumor type-specific proteins can be used for both cancer screening and identification of the tumor’s origin [142,143].